7.6. adjuvant therapy. 7.6.1. role adjuvant platinum-based chemotherapy adjuvant chemotherapy rc patients pt3/4 and/or ln positive (n+) disease without clinically detectable metastases (m0) still debate. general benefits adjuvant chemotherapy include: chemotherapy administered accurate pathological staging, therefore, treatment patients low risk micrometastases avoided;no delay definitive surgical treatment. drawbacks adjuvant chemotherapy are: assessment vivo chemosensitivity tumour possible overtreatment unavoidable problem;delay intolerability chemotherapy, due post-operative morbidity . limited evidence adequately conducted accrued phase iii rcts favour routine use adjuvant chemotherapy [464-469]. individual patient data meta-analysis survival data six rcts adjuvant chemotherapy [471-473] included 491 patients (unpublished data otto et al., included analysis). included trials suffered significant methodological flaws including small sample size (underpowered), incomplete accrual, use inadequate statistical methods design flaws (irrelevant endpoints failing address salvage chemotherapy case relapse metastases) . trials, three four cycles cmv, cisplatin, cyclophosphamide, adriamycin (cisca), methotrexate, vinblastine, adriamycin epirubicin, cisplatin (mva(e)c) cisplatin methotrexate (cm) used , one trial used cisplatin monotherapy . data convincing support unequivocal recommendation use adjuvant chemotherapy. 2014, meta-analysis updated additional three studies [467-469] resulting inclusion 945 patients nine trials . none trials fully accrued individual patient data used analysis . one trial abstract available time meta-analysis none included individual trials significantly positive os favour adjuvant chemotherapy. two trials modern chemotherapy regimens used (gemcitabine/cisplatin paclitaxel/gemcitabine/cisplatin) . hr os 0.77 (95% ci: 0.59–0.99, p = 0.049) dfs 0.66 (95% ci: 0.45–0.91, p = 0.014) stronger impact dfs case nodal positivity. recently, systematic review meta-analysis individual patient data rcts patients treated adjuvant cisplatin-based chemotherapy mibc conducted . analysis 10 rcts (n = 1,183), os benefit demonstrated cisplatin-based adjuvant chemotherapy (hr: 0.82, 95% ci: 0.70–0.96, p = 0.02). translates absolute improvement survival 6% 5 years, 50% 56%, 9% absolute benefit adjusted age, sex, pt stage, pn category (hr: 0.77, 95% ci: 0.65–0.92, p = 0.004). adjuvant chemotherapy also shown improve rfs (hr: 0.71, 95% ci: 0.60-0.83, p < 0.001), locoregional rfs (hr: 0.68, 95% ci: 0.55–0.85, p < 0.001), mfs (hr: 0.79, 95% ci: 0.65–0.95, p = 0.01), absolute benefits 11%, 11%, 8%, respectively. retrospective cohort analysis including 3,974 patients cystectomy lnd showed os benefit high-risk subgroups (extravesical extension nodal involvement) (hr: 0.75, ci: 0.62–0.90) . publication largest rct (european organisation research treatment cancer [eortc] 30994), although fully accrued, showed significant improvement pfs immediate, compared deferred, cisplatin-based chemotherapy (hr: 0.54, 95% ci: 0.4–0.73, p < 0.0001), significant os benefit . furthermore, large observational study including 5,653 patients pathological t3–4 and/ pathological node-positive bc, treated 2003 2006 compared effectiveness adjuvant chemotherapy vs. observation. twenty-three percent patients received adjuvant chemotherapy 5-year os 37% adjuvant arm vs. 29.1% (hr: 0.70, 95% ci: 0.64–0.76) observation group . another large retrospective analysis based u.s. national cancer database including 15,397 patients locally-advanced (pt3/4) ln-positive disease also demonstrated os benefit patients uc histology . patients concomitant histological subtypes, however, benefit found. patients informed potential chemotherapy options rc limited evidence adjuvant chemotherapy. 7.6.2. role adjuvant immunotherapy determine benefit pd-1/pd-l1 checkpoint inhibitors, three phase iii rcts evaluated checkpoint inhibitor monotherapy atezolizumab, nivolumab pembrolizumab patients muscle-invasive uc. checkmate 274 phase iii multi-centre, double-blind, rct adjuvant nivolumab vs. placebo 1 year 709 patients muscle-invasive uc high risk recurrence (pathological stage pt3, pt4a, pn+) (neoadjuvant cisplatin-based chemotherapy allowed trial entry) demonstrated significant improvement median dfs (20.8 months [95% ci: 16.5–27.6] nivolumab 10.8 months [95% ci: 8.3–13.9] placebo). percentage patients alive disease-free 6 months 74.9% nivolumab 60.3% placebo (hr disease recurrence death, 0.70; 98.22% ci: 0.55–0.90; p < 0.001). among patients pd-l1 expression level ≥ 1% (tumor cell [tc] score), percentage patients 74.5% 55.7%, respectively (hr: 0.55; 98.72% ci: 0.35–0.85; p < 0.001) . analysis using pd-l1 tc score combined positive score (cps), patients cps ≥ 1 tc ≥ 1% patients cps ≥ 1 improved dfs nivolumab may contributed benefit seen adjuvant nivolumab patients tc < 1% cps ≥ 1 . clinically meaningful deterioration health-related quality life adjuvant nivolumab compared placebo . primary endpoint dfs achieved multi-centre rct adjuvant atezolizumab vs. observation patients ypt2–4a ypn+ tumours following nac pt3–4a pn+ tumours nac received (imvigor010). median dfs 19.4 months (95% ci: 15.9–24.8) atezolizumab 16.6 months (11.2–24.8) observation (stratified hr: 0.89, 95% ci: 0.74–1.08, p = 0.24) . similarly designed trial pembrolizumab adjuvant setting completed accrual results awaited. fda approved nivolumab adjuvant treatment patients uc high risk recurrence undergoing surgery whereas ema approved adjuvant nivolumab treatment adults muscle-invasive uc (miuc) tumour cell pd-l1 expression ≥ 1%, high risk recurrence undergoing radical resection miuc. promising report (see marker section) suggested potential role ctdna guide use adjuvant io uc . 7.6.3. summary evidence guidelines adjuvant therapy summary evidenceleadjuvant cisplatin-based chemotherapy high-risk patients (pt3, 4 and/or n+ m0) without neoadjuvant treatment associated improvement dfs os trials underpowered adequately answer question.2ato date, studies immune checkpoint inhibitors adjuvant setting patients high-risk mibc received nac demonstrated conflicting results checkmate 274 study demonstrating improvement dfs adjuvant nivolumab imvigor 010 study failing show improvement dfs adjuvant atezolizumab.1bcirculating tumour dna holds promise prognostic predictive biomarker guide use adjuvant io uc patients high risk recurrence positive ctdna treated adjuvant atezolizumab demonstrating improved outcomes compared observation.2b recommendationsstrength ratingoffer adjuvant cisplatin-based combination chemotherapy patients pt3/4 and/or pn+ disease neoadjuvant chemotherapy given.strongoffer adjuvant nivolumab selected patients pt3/4 and/or pn+ disease eligible for, declined, adjuvant cisplatin-based chemotherapy.weak